Why These Two Peptides Work Together
BPC-157 and TB-500 address different phases of the healing cascade. BPC-157 research focuses on angiogenesis and growth factor signaling — building the vascular infrastructure that injured tissue needs. TB-500 research focuses on cellular migration — getting repair cells to the injury site. Together they address complementary aspects of tissue repair that neither compound covers alone.
What the Research Shows
Animal studies on BPC-157 consistently show accelerated healing of tendons, ligaments, and muscle tissue. TB-500 studies show improved wound closure rates and cellular mobility. Both are now Category 1 compounds following the February 2026 FDA reclassification, making them legally prescribable through licensed 503A pharmacies.
How a Physician Designs This Protocol
A physician prescribing this protocol considers your specific injury or recovery goal, your medical history, current medications, and body weight. Dose, administration route (subcutaneous injection vs oral), frequency, and protocol duration are all individualized. This is not a one-size-fits-all compound menu — it is a clinical decision made by a licensed physician who knows your case.
What to Expect
Most research protocols run 4-12 weeks. Physician check-ins at week 2 and week 4 allow for dose adjustment based on response. A 90-day physician review assesses outcomes and determines whether to continue, adjust, or conclude the protocol.